ATE406917T1 - Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür - Google Patents

Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür

Info

Publication number
ATE406917T1
ATE406917T1 AT02796357T AT02796357T ATE406917T1 AT E406917 T1 ATE406917 T1 AT E406917T1 AT 02796357 T AT02796357 T AT 02796357T AT 02796357 T AT02796357 T AT 02796357T AT E406917 T1 ATE406917 T1 AT E406917T1
Authority
AT
Austria
Prior art keywords
carrier
fine particles
production method
composition containing
active ingredients
Prior art date
Application number
AT02796357T
Other languages
English (en)
Inventor
Kazunori Kataoka
Yoshinori Kakizawa
Original Assignee
Toudai Tlo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toudai Tlo Ltd filed Critical Toudai Tlo Ltd
Application granted granted Critical
Publication of ATE406917T1 publication Critical patent/ATE406917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Electrophotography Configuration And Component (AREA)
  • Dry Development In Electrophotography (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02796357T 2001-08-27 2002-08-27 Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür ATE406917T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001256125 2001-08-27

Publications (1)

Publication Number Publication Date
ATE406917T1 true ATE406917T1 (de) 2008-09-15

Family

ID=19083982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796357T ATE406917T1 (de) 2001-08-27 2002-08-27 Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür

Country Status (7)

Country Link
US (1) US7897176B2 (de)
EP (1) EP1431347B1 (de)
JP (2) JP2003523544A (de)
AT (1) ATE406917T1 (de)
CA (1) CA2458837C (de)
DE (1) DE60228742D1 (de)
WO (1) WO2003018690A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480770A1 (en) * 2002-04-03 2003-10-09 Japan Science And Technology Agency Biochip sensor surface carrying polyethylene glycolated nanoparticles
WO2007116965A1 (ja) * 2006-04-12 2007-10-18 Toray Industries, Inc. グラフトポリマーとカルシウム化合物とを含む微粒子
US20100003301A1 (en) * 2006-11-11 2010-01-07 The University Of Tokyo Bone Defect Filler, Release-Controlled Carrier, And Their Production Methods
JP5081439B2 (ja) * 2006-12-07 2012-11-28 独立行政法人科学技術振興機構 造影剤含有有機−無機ハイブリッド型粒子
CN101686939B (zh) * 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
JP2011010549A (ja) * 2007-10-29 2011-01-20 Univ Of Tokyo ポリエチレングリコールの結合した核酸のコンジュゲートとリン酸カルシウムの有機−無機ハイブリッド型ナノ粒子
WO2009093713A1 (ja) * 2008-01-25 2009-07-30 Ebara Corporation ペグ修飾ハイドロキシアパタイト及びそれを基材とする医薬とその製造方法
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
EP2457588A1 (de) 2010-11-05 2012-05-30 UMC Utrecht Holding B.V. Mikrosphäre mit Lanthanid-Metallkomplex
CN113908137B (zh) * 2021-10-27 2023-04-11 高州市人民医院 一种注射用硬核软膜型纳米缓释递药系统的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517111A (ja) 1991-02-21 1993-01-26 Ricoh Co Ltd 水酸アパタイト超微粒子
US5368869A (en) * 1993-03-09 1994-11-29 Utah State University Foundation Compositions and methods for manufacturing a skim or lowfat milk product with increased creaminess, color, mouthfeel, and taste sensations similar to milk with a higher fat content
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
KR100566911B1 (ko) 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체

Also Published As

Publication number Publication date
US7897176B2 (en) 2011-03-01
JPWO2003018690A1 (ja) 2004-12-09
JP4641721B2 (ja) 2011-03-02
EP1431347B1 (de) 2008-09-03
JP2003523544A (ja) 2003-08-05
EP1431347A4 (de) 2006-08-30
CA2458837A1 (en) 2003-03-06
DE60228742D1 (de) 2008-10-16
CA2458837C (en) 2009-12-15
EP1431347A1 (de) 2004-06-23
WO2003018690A1 (en) 2003-03-06
US20040197360A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE406917T1 (de) Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür
UA66952C2 (uk) N-(5,7-диметокси[1,2,4]триазоло[1,5-a]піримідин-2-іл)арилсульфонамід, спосіб його одержання, композиція на його основі та спосіб боротьби з небажаною рослинністю
DE69431660D1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäuren, ihre komplexe und derivate zur verwendung als kontrastmittel
DE60139625D1 (de) Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
FI960546A0 (fi) Polymeerin stabilointi stabiililla vapaalla radikaalilla
DE69434980D1 (de) Stabile bakterizide Proteine, welche die Permeabilität erhöhen und pharmazeutische Zusammensetzungen, diese enthaltend
BR0316886A (pt) Composição, processo para a preparação de uma composição, produto para contraste, usos de uma composição e uso de partìculas magnéticas
GR3030703T3 (en) Process for the production of biologically active protein (e.g. TGF)
ATE227983T1 (de) Methoden zur verhütung von kristallwachstum und partikelaggregation in nanopartikelzusammensetzungen
AU7779900A (en) Trifluoromethyl-substituted spirocyclic ketoenols
DE69714253D1 (de) Stickstoffoxydabgebendes präparat zur reduzierung der toxizität von wirkstoffen
TR199800608A2 (en) Propanolamin t�revleri, bunlar�n �retim usul�.
DE59608422D1 (de) Verfahren zur Herstellung von Poly(diorganosiloxanen), Mischungen, enthaltend diese Poly(diorganosiloxane) und deren Verwendung
DE3585865D1 (de) Eine enzymzusammensetzung als verdauungsbeschleuniger bei verschiedenen spiegeln im verdauungskanal und deren herstellungsverfahren.
ATE149993T1 (de) Organische cerium-iv-verbindungen und deren herstellung und verwendung
EP0321968A3 (en) Compounds active on the cardiovascular system
DE3750857D1 (de) Imidazolsulfonamid-Derivate, Herbizide und Verfahren zur Bekämpfung von Schadpflanzen.
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
ATE305612T1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
DE60022751D1 (de) Mittel zur stabilisierung von hämoglobinen
DE60034941D1 (de) Essentielles material und verfahren zu dessen herstellung
DE69901088D1 (de) 1,2-Dithiolan Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
DE60020871D1 (de) Formulierungen mit verlängerter freisetzung zur implantation
ATE286746T1 (de) Proteinhaltige hydrogele
DK427388A (da) Farmaceutiske midler indeholdende trapidil samt fremgangsmaade til fremstilling heraf

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties